Home / Market News / $BMY
benzinga Corporate Catalyst Impact 65/100 ● negative

Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

Oct 5, 2026, 1:04 PM UTC · Primary ticker $BMY

Leerink Partners downgraded Bristol-Myers Squibb (BMY) from Outperform to Market Perform and reduced its price target from $73 to $59. This analyst action suggests a revised outlook on the company's future performance, likely impacting investor sentiment and potentially the stock price in the short term.

Leerink Partners analyst David Risinger downgraded Bristol-Myers Squibb (BMY) from 'Outperform' to 'Market Perform' and significantly lowered the price target from $73 to $59. This action indicates a more cautious outlook on BMY's prospects, likely due to concerns about pipeline developments, competitive pressures, or financial performance. For traders, this downgrade could lead to short-term selling pressure on BMY stock as investors react to the revised analyst sentiment. While not a fundamental change in the company's operations, a notable downgrade from a prominent firm can influence market perception and potentially create a trading opportunity for those anticipating a downward movement.

$BMY negative Analyst downgrade and price target reduction
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.